GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
Subscribe To Our Newsletter & Stay Updated
